DISORIENTASI DAN GANGGUAN MEMORI SETELAH VAKSINASI COVID-19 (CORONAVAC): LAPORAN KASUS
DOI:
https://doi.org/10.29303/jku.v12i1.863Kata Kunci:
Vaksin COVID-19 , CoronaVac, Disorientasi, Gangguan MemoriAbstrak
Vaksinasi merupakan strategi yang penting dalam menghadapi pandemi Coronavirus Disease 2019 (COVID-19). Beberapa Kejadian Ikutan Paska Imunisasi (KIPI) di bidang neurologi telah dilaporkan dan menjadi perhatian khusus terhadap keamanan vaksinasi COVID-19. Kami melaporkan kasus seorang laki-laki usia 35 tahun datang ke Instalasi Gawat Darurat dengan keluhan tidak ingat anggota keluarganya setelah menerima vaksin CoronaVac dosis kedua. Pasien pulih sepenuhnya setelah mendapatkan perawatan dalam 24 jam. Disorientasi dan gangguan memori setelah vaksinisasi COVID-19 pada kasus ini kemungkinan disebabkan oleh hiperkoagulasi akibat vaksinasi atau akibat koinsidensi yang selanjutnya menyebabkan terjadinya gangguan cerebrovaskular. Disorientasi dan gangguan memori setelah vaksinasi CoronaVac merupakan kasus yang jarang terjadi dan perlu diwaspadai. Saat ini, manfaat pemberian vaksin lebih besar daripada risiko efek samping. Dengan demikian, vaksinasi terhadap COVID-19 harus tetap didorong untuk dilaksanakan.
Referensi
2. Lenzen M, Li M, Malik A, Pomponi F, et al. Global socio-economic losses and environmental gains from the Coronavirus pandemic. PLoS ONE. 2020. 15(7): e0235654.
3. Masyeni, S, Johar, E, Budhitresna, AAG.et al. Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study. COVID 2022, 2, 485–491.
4. Fadlyana, E, Rusmil, K, Tarigan, R, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia. Vaccine 2021, 39, 6520–8.
5. Tanriover, MD, Do?ganay, HL, Akova, M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021, 398, 213–222.
6. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403e416.
7. Vitiello A, Ferrara, F, Troiano V, et al. COVID-19 vaccines and decreased transmission of SARS-CoV-2. Inflammopharmacology 2021. 29 (5), 1357–1360.
8. Sriwastava S, Sharma K, Khalid SH, et al. COVID-19 Vaccination and Neurological Manifestations: A Review of Case Reports and Case. Series. Brain Sci. 2022, 12, 407. 1-14
9. Lu L, Xiong W, Mu J, et al. The potential neurological effect of the COVID-19 vaccines: A review. Acta Neurol. Scand. 2021, 144, 3–12.
10. Prasad A, Hurlburt, G, Podury, S, et al. A Novel Case of Bifacial Diplegia Variant of Guillain-Barré; Syndrome Following Janssen COVID-19 Vaccination. Neurol. Int. 2021, 13, 404–409.
11. Chaurasia B, Chavda V, Lu B, et al. Cognitive deficits and memory impairments after COVID-19 (Covishield) vaccination. Brain Behav Immun Health. 2022; 22:100463.
12. Hameed S, Khan AF, Khan S, et al. First Report of Cerebral Venous Thrombosis Following Inactivated-Virus Covid Vaccination (Sinopharm and Sinovac). J Stroke Cerebrovasc Dis. 2022;31(3):106298.
13. Hidayat R, Diafiri D, Zairinal RA, et al. Acute Ischaemic Stroke Incidence after Coronavirus Vaccine in Indonesia: Case Series. Curr Neurovasc Res. 2021;18(3):360-363.
14. Sahin U, Muik A, Derhovanessian, E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature 2021, 586, 594–599, Erratum in: Nature 2021, 590, E17.
15. Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination. Nature 2021, 600, 701–706.
16. Blauenfeldt RA, Kristensen SR, Ernstsen SL, et al. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J. Thromb. Haemostasis. 2021. 19 (7), 1771–1775
17. Malik, B., Kalantary, A, Rikabi, K, et al. Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine. BMJ Case Rep. 2021. 14 (7), e243975
18. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination N Engl J Med, 384 (2021), 2092-101.
19. Noikongdee P, Police P, Phojanasenee T, et al.Prevalence of anti-platelet factor 4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais Res Pract Thromb Haemost, 5. 2021, Article e12600
20. Simpson CR, Shi T, Vasileiou E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland Nat Med.2021. 27; 1290-7.
21. S Pavord, M Scully, BJ Hunt, et al.Clinical features of vaccine-induced immune thrombocytopenia and thrombosis N Engl J Med, 2021.385; 1680-1689
22. Ren C, Yuan J, Tong S, et al. Memory Impairment Due to a Small Acute Infarction of the Columns of the Fornix. J Stroke Cerebrovasc Dis. 2018;27;7: e138-e143
23. Kim YS, Park HY, Yun KH, Park H, Cheong JS, Ha YS. Association of aortic knob calcification with intracranial stenosis in ischemic stroke patients. J Stroke. 2013;15(2):122-125
24. Hermann DM, Lehmann N, Gronewold J, et al. Thoracic aortic calcification is associated with incident stroke in the general population in addition to established risk factors. Eur Heart J Cardiovasc Imaging. 2015;16(6):684-690.
25. Park Y, Park HY, Yun KH, et al. The clinical significance of aortic calcification in chest radiography in community-dwelling, healthy adults: The PRESENT project. Neurology Asia 2019; 24(1): 1 – 7.